Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXW92T)

• Drug Name: Ixekizumab Drug Info
• Synonyms: LY2439821

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Approved	[1]
Psoriatic arthritis	FA21	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DMXW92T

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-17 (IL17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[4]
Bimekizumab	DMR9TF1	Plaque psoriasis	EA90.0	Approved	[5]
CNTO-6785	DM6RQXB	Rheumatoid arthritis	FA20	Phase 2	[6]
ABT-122	DM23UQ9	Psoriatic arthritis	FA21	Phase 2	[7]
CJM112	DMTSVJM	Acne vulgaris	ED80	Phase 2	[8]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[9]
SHR-1314	DMADNY3	Plaque psoriasis	EA90.0	Phase 1/2	[5]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[10]
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[9]
SCH-900117	DM7A6R5	Rheumatoid arthritis	FA20	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-17 (IL17)	TTG0MT6	IL17_HUMAN	Modulator	[3]

References

• [1] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7541).
• [3] Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
• [7] DOI: 10.1136/annrheumdis-2015-eular.4042
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.